혈장 유도체 시장 : 제품 유형, 용도, 최종사용자, 공급원별 - 세계 예측(2025-2030년)

The Blood Plasma Derivatives Market was valued at USD 483.24 million in 2023, expected to reach USD 523.83 million in 2024, and is projected to grow at a CAGR of 9.65%, to USD 921.33 million by 2030.

Blood plasma derivatives refer to therapeutic products originating from human plasma, including immunoglobulins, clotting factors, albumin, and others, used to treat a variety of medical conditions. The necessity of these derivatives stems from their vital role in treating immunodeficiency disorders, hemophilia, and autoimmune diseases, among others, which are on the rise globally due to increased diagnosis and awareness. The end-use scope primarily encompasses hospitals, clinics, and research institutions, where such therapeutics are crucial for life-saving interventions. The market is significantly influenced by factors like technological advancements in plasma fractionation, government initiatives to improve healthcare infrastructure, and increased collaborations between research institutions and pharmaceutical companies. An aging population and higher prevalences of chronic diseases further amplify market growth. However, stringent regulatory policies and the high cost of production pose notable challenges. Furthermore, ethical concerns related to plasma donation processes and potential risks of transfusion-transmitted infections hinder market expansion. Nevertheless, advancements in genetic research and biotechnology present opportunities for development of more efficient and recombinant plasma-derived products. Focusing on improving plasma collection processes and enhancing supply chain efficiency can mitigate some limitations. Innovations in synthetic biology open channels for more sustainable and ethical production methodologies, possibly reducing dependence on human donors. Business growth can be achieved by investing in R&D partnerships to explore these areas, ensuring streamlined and compliant production, and by expanding geographical reach to emerging markets witnessing an upsurge in healthcare spending. Additionally, enhancing patient and healthcare provider education on the benefits of plasma-derived products could foster market acceptance and usage. Overall, the market is poised for growth with potential innovations paving the way for less costly and ethically sound alternatives.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Plasma Derivatives Market

The Blood Plasma Derivatives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
  • Rising investments in healthcare infrastructure and advanced plasma collection technologies
  • Government initiatives and favorable policies supporting blood plasma derivative research and development
  • Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
• Market Restraints
  • Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
  • Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
• Market Opportunities
  • Expanding use of plasma-derived therapies in oncology and critical care
  • Technological advancements improving production efficiency of plasma derivatives
  • Government initiatives promoting the use of plasma products in public health emergencies
• Market Challenges
  • High cost of blood plasma collection and processing limiting market expansion
  • Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market

Porter's Five Forces: A Strategic Tool for Navigating the Blood Plasma Derivatives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Plasma Derivatives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Plasma Derivatives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Plasma Derivatives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Plasma Derivatives Market

A detailed market share analysis in the Blood Plasma Derivatives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Plasma Derivatives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Plasma Derivatives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Plasma Derivatives Market

A strategic analysis of the Blood Plasma Derivatives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Plasma Derivatives Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, ARTHREX GmbH, Bio Products Laboratory Ltd, Biotest AG, BPL Holdings, China Biologic Products Holdings, Inc., CSL Behring, Emergent BioSolutions, Grifols, Intas Pharmaceuticals, Kamada Ltd., Kedrion Biopharma, LFB Group, Octapharma, Prothya Biosolutions, RAAS Blood Products, Sanquin, Shanghai RAAS Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Blood Plasma Derivatives Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Albumin, Coagulation Factors, and Immunoglobulins. The Coagulation Factors is further studied across Factor IX, Factor VIII, Fibrinogen Concentrate, and Prothrombin Complex Concentrate (PCC). The Immunoglobulins is further studied across Intravenous (IVIG) and Subcutaneous (SCIG).
• Based on Application, market is studied across Diagnostics, Research, and Therapeutic Use. The Therapeutic Use is further studied across Cardiology, Hemato-oncology, Immunology, Infectious Diseases, Neurology, Pulmonology, and Trauma Emergencies.
• Based on End User, market is studied across Academic & Research Institutes, Blood Banks, Clinics, Diagnostic Laboratories, and Hospitals.
• Based on Source, market is studied across Human Plasma and Non-Human Plasma.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
    • 5.1.1.2. Rising investments in healthcare infrastructure and advanced plasma collection technologies
    • 5.1.1.3. Government initiatives and favorable policies supporting blood plasma derivative research and development
    • 5.1.1.4. Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
  • 5.1.2. Restraints
    • 5.1.2.1. Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
    • 5.1.2.2. Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
  • 5.1.3. Opportunities
    • 5.1.3.1. Expanding use of plasma-derived therapies in oncology and critical care
    • 5.1.3.2. Technological advancements improving production efficiency of plasma derivatives
    • 5.1.3.3. Government initiatives promoting the use of plasma products in public health emergencies
  • 5.1.4. Challenges
    • 5.1.4.1. High cost of blood plasma collection and processing limiting market expansion
    • 5.1.4.2. Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Blood Plasma Derivatives Market, by Product Type

• 6.1. Introduction
• 6.2. Albumin
• 6.3. Coagulation Factors
  • 6.3.1. Factor IX
  • 6.3.2. Factor VIII
  • 6.3.3. Fibrinogen Concentrate
  • 6.3.4. Prothrombin Complex Concentrate (PCC)
• 6.4. Immunoglobulins
  • 6.4.1. Intravenous (IVIG)
  • 6.4.2. Subcutaneous (SCIG)

7. Blood Plasma Derivatives Market, by Application

• 7.1. Introduction
• 7.2. Diagnostics
• 7.3. Research
• 7.4. Therapeutic Use
  • 7.4.1. Cardiology
  • 7.4.2. Hemato-oncology
  • 7.4.3. Immunology
  • 7.4.4. Infectious Diseases
  • 7.4.5. Neurology
  • 7.4.6. Pulmonology
  • 7.4.7. Trauma Emergencies

8. Blood Plasma Derivatives Market, by End User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Blood Banks
• 8.4. Clinics
• 8.5. Diagnostic Laboratories
• 8.6. Hospitals

9. Blood Plasma Derivatives Market, by Source

• 9.1. Introduction
• 9.2. Human Plasma
• 9.3. Non-Human Plasma

10. Americas Blood Plasma Derivatives Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Blood Plasma Derivatives Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Blood Plasma Derivatives Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ADMA Biologics
• 2. ARTHREX GmbH
• 3. Bio Products Laboratory Ltd
• 4. Biotest AG
• 5. BPL Holdings
• 6. China Biologic Products Holdings, Inc.
• 7. CSL Behring
• 8. Emergent BioSolutions
• 9. Grifols
• 10. Intas Pharmaceuticals
• 11. Kamada Ltd.
• 12. Kedrion Biopharma
• 13. LFB Group
• 14. Octapharma
• 15. Prothya Biosolutions
• 16. RAAS Blood Products
• 17. Sanquin
• 18. Shanghai RAAS Blood Products Co., Ltd.
• 19. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
• 20. Takeda Pharmaceutical Company Limited